Insider Shareholders with Direct Ownership of Prelude Therapeutics Inc (PRLD)
This section provides a comprehensive overview of the insiders with direct ownership of Prelude Therapeutics Inc (PRLD). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Prelude Therapeutics Inc Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Krishna Vaddi
CEO |
121,756 | 0 | 1,067,275 $1.27 Million | 5 |
May 25, 2023
Added 0.08%
|
| 448,370 | 0 | 500,098 $595,116 | 1 |
Sep 29, 2020
Added 23.38%
|
|
|
Andrew Combs
Chief Chemistry Officer |
44,062 | 0 | 304,442 $362,285 | 3 |
Mar 31, 2022
Added 10.59%
|
|
Peggy Scherle
Chief Scientific Officer |
60,000 | 60,000 | 172,920 $205,774 | 14 |
Aug 27, 2021
Reduced 0.35%
|
|
Jane Huang
President, CMO |
93,750 | 30,409 | 63,341 $75,375 | 13 |
Oct 04, 2024
Reduced 5.02%
|
|
Laurent Chardonnet
Chief Financial Officer |
36,500 | 0 | 42,165 $50,176 | 5 |
May 23, 2023
Added 10.6%
|
|
Bryant David Lim
CLO, Interim CFO, Corp Sec. |
27,400 | 0 | 27,400 $32,606 | 2 |
Dec 19, 2024
Added 47.71%
|
|
Christopher Pierce
EVP and Chief of Business Oper |
21,323 | 21,323 | 3,750 $4,462 | 8 |
Sep 02, 2021
Reduced 64.89%
|
|
Deborah Morosini
EVP, Chief of Clinical Affairs |
61,825 | 61,825 | 444 $528 | 10 |
Dec 15, 2021
Reduced 98.48%
|
|
David J Mauro
Chief Medical Officer |
165,000 | 165,000 | 0 $0 | 20 |
Oct 05, 2021
Reduced 100.0%
|
|
Brian Piper
Chief Financial Officer |
16,666 | 16,666 | 0 $0 | 4 |
Aug 25, 2021
Reduced 100.0%
|